The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S10-S16 , September 2007

Abdominal Adiposity and Cardiometabolic Risk: Do We Have All the Answers?

  • Steven M. Haffner, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Steven M. Haffner, MD, Department of Medicine and Clinical Epidemiology, University of Texas Health Science Center, 7703 Floyd Curl Drive, MC 7873, San Antonio, Texas, 78240.

References 

  1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200
  2. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US, 1990–1998. Diabetes Care. 2000;23:1278–1283
  3. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991–1998. JAMA. 1999;282:1519–1522
  4. National Institutes of Health. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute/North American Association for the Study of Obesity; 2000;October NIH Publication No. 00-4084.
  5. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097–1105
  6. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–778
  7. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779–787
  8. Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women. JAMA. 1993;269:483–487
  9. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997;273(pt 1):E425–E432
  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. [IDF Website.]. 2006;Available at: http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf. Accessed March 13,
  12. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. [published correction appears in Circulation. 2005;112:e297–e298] Circulation. 2005;112:2735–2752
  13. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47
  14. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850
  15. Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:797–810
  16. Hanley AJG, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2004;53:2623–2632
  17. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes. 2005;54:3140–3147
  18. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251–1257
  19. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153–3159
  20. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–569
  21. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial function in obese women after weight loss over one year. Circulation. 2002;105:804–809
  22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  23. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619
  24. Després J-P, Golay A, Sjostrom L Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134
  25. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight and obese patients. JAMA. 2006;295:761–775
  26. National Institute of Diabetes & Digestive & Kidney Diseases. Look Ahead: Action for Health in Diabetes Study. [NIDDK Website.]. Available at: http://www.niddk.nih.gov/patient/SHOW/lookahead.htm. Accessed July 24, 2006.

PII: S0002-9343(07)00545-1

doi: 10.1016/j.amjmed.2007.06.006

The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S10-S16 , September 2007

Article Tools

* Image Usage & Resolution